Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03386344 |
|
Recruitment Status :
Terminated
(Study terminated prematurely for financial reasons and Covid-19 pandemic.)
First Posted : December 29, 2017
Results First Posted : June 25, 2021
Last Update Posted : June 25, 2021
|
Sponsor:
Lexicon Pharmaceuticals
Collaborator:
Sanofi
Information provided by (Responsible Party):
Lexicon Pharmaceuticals
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective is to demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (Hb1Ac) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on diet and exercise only or with a stable antidiabetes regimen.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 2 Diabetes Mellitus | Drug: Sotagliflozin Drug: Placebo | Phase 3 |
Study duration per participant is approximately 110 weeks (Screening period of up to 2 weeks, 2 week single-blind run-in period), a 26-week double-blind core treatment period, a 78-week double-blind extension period, and a 2- week post treatment follow up period.
Dual-energy X-ray absorptiometry (DXA) scans will be performed to assess Bone Mineral Density and Fat vs. Lean body mass at baseline and Weeks 26, 52, and 104.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 376 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control |
| Actual Study Start Date : | February 19, 2018 |
| Actual Primary Completion Date : | May 22, 2019 |
| Actual Study Completion Date : | May 30, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Type 2 diabetes
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
|
Drug: Placebo
Pharmaceutical form: Tablet; Route of administration: Oral |
|
Experimental: Sotagliflozin 200 mg
Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
|
Drug: Sotagliflozin
Pharmaceutical form: Tablet; Route of administration: Oral
Other Name: SAR439954 Drug: Placebo Pharmaceutical form: Tablet; Route of administration: Oral |
|
Experimental: Sotagliflozin 400 mg
Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
|
Drug: Sotagliflozin
Pharmaceutical form: Tablet; Route of administration: Oral
Other Name: SAR439954 |
Primary Outcome Measures :
- Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [ Time Frame: Baseline to Week 26 ]An analysis of covariance (ANCOVA) model is used for analysis.
Secondary Outcome Measures :
- Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Week 26 [ Time Frame: Baseline to Week 26 ]An ANCOVA model is used for analysis.
- Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Week 26 [ Time Frame: Baseline to Week 26 ]An ANCOVA model is used for analysis.
- Percent Change From Baseline in Bone Mineral Density (BMD) of Femoral Neck at Week 26 [ Time Frame: Baseline to Week 26 ]An ANCOVA model is used for analysis.
- Change From Baseline in Body Weight at Week 26 [ Time Frame: Baseline to Week 26 ]An ANCOVA model is used for analysis.
- Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 [ Time Frame: Baseline to Week 26 ]An ANCOVA model is used for analysis.
- Change From Baseline in Systolic Blood Pressure (SBP) at Week 12 [ Time Frame: Baseline to Week 12 ]An ANCOVA model is used for analysis.
- Percentage of Participants With Hemoglobin A1c (HbA1c) <7.0% at Week 26 [ Time Frame: Week 26 ]
- Percentage of Participants With Adverse Events (AEs) [ Time Frame: up to 106 weeks ]An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria :
- Participants with T2D managed with diet and exercise only or with a stable antidiabetes regimen (in monotherapy or combination therapy that can include oral antidiabetes medications, insulin, or glucagon-like peptide-1 agonists) for more than 12 weeks.
- Participants has given written informed consent to participate in the study in accordance with local regulations.
Exclusion criteria:
- Age <55 years.
- Women who have been postmenopausal (or undergone bilateral oophorectomy) for less than 5 years.
- Type 1 diabetes mellitus.
- Body mass index (BMI) ≤20 or >45 kilogram per meter square kg/m^2 or bodyweight that exceeds the weight limits of the DXA scanner.
- Hemoglobin A1C (HbA1c) <7.0% or HbA1c >11.0%.
- Use of a selective sodium-glucose cotransporter type 2 (SGLT2) inhibitor or thiazolidinedione within 24 months.
- Bone mineral density (BMD) T- score <-2.0 at any site (ie, lumbar spine, total hip, or femoral neck).
- History of fracture within 12 months (except for fractures of the hand/fingers, foot/toes, facial bones, and skull).
- Treatment with medications known to affect bone mass or modify the risk of fractures within 36 months (eg, bisphosphonates, selective estrogen receptor modulators, calcitonin, teriparatide, denosumab, strontium ranelate, growth hormone, aromatase inhibitors, androgen deprivation therapy, carbamazepine, phenytoin, and phenobarbital). Use of hormonal replacement that includes systemic or transdermal estrogen or testosterone is excluded unless is stable for at least 24 months prior to Screening.
- Lower extremity complications (such as skin ulcers, infection, osteomyelitis and gangrene) identified during the Screening period, and still requiring treatment at randomization.
- Uncontrolled high blood pressure, severe anemia, severe cardiovascular problems, such as heart failure, active cancer, or other conditions that the Investigator believes with result in a short life expectancy.
- Renal disease as defined by an estimated glomerular filtration rate (eGFR) <30 milliliter per minute (mL/min)/1.73 meter square (m^2) at the Screening Visit by the 4 variable Modification of Diet in Renal Disease equation.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03386344
Locations
Show 53 study locations
Sponsors and Collaborators
Lexicon Pharmaceuticals
Sanofi
Investigators
| Study Director: | Suman Wason, MD | Lexicon Pharmaceuticals, Inc. |
Study Documents (Full-Text)
Documents provided by Lexicon Pharmaceuticals:
Documents provided by Lexicon Pharmaceuticals:
Study Protocol [PDF] November 14, 2017
Statistical Analysis Plan [PDF] January 31, 2020
| Responsible Party: | Lexicon Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03386344 |
| Other Study ID Numbers: |
EFC15294 2017-002041-30 U1111-1195-6371 ( Other Identifier: UTN ) |
| First Posted: | December 29, 2017 Key Record Dates |
| Results First Posted: | June 25, 2021 |
| Last Update Posted: | June 25, 2021 |
| Last Verified: | June 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol Sodium-Glucose Transporter 2 Inhibitors Molecular Mechanisms of Pharmacological Action Hypoglycemic Agents Physiological Effects of Drugs |